NCT01719250View on ClinicalTrials.gov

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 16, 2016

Study Completion Date

March 22, 2017

Conditions
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell LymphomaTransformed Recurrent Non-Hodgkin Lymphoma
Interventions
DRUG

Buparlisib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT01719250 - Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter